Immune Pharmaceuticals raises $11.7m on Nasdaq
Biotech billionaire Prof. Shlomo Ben-Haim is facing his third lawsuit this year and fourth in his career over the life sciences companies he founded.
Biotech billionaire Prof. Shlomo Ben-Haim is facing his third lawsuit this year and fourth in his career over the life sciences companies he founded. He has been sued twice by entrepreneurs of companies he founded, who accused him of stealing their assets. He was once sued by his former partner and friend, Lewis Pell for alleged unfair distribution of assets between them. The question arises whether the string of lawsuits is because of Ben-Haim's deep pockets, or is he a serial dispossessor?
Ben-Haim is considered one of the most prominent and successful investors in Israel's life sciences industry. He started out as a cardiologist at Rambam Medical Center in Haifa, and was considered a genius as a doctor and as an engineer. Pell, the US life sciences investor who began his Israeli activities at the time, met Ben-Haim and they began to work together, and it turned out that Ben-Haim also had a talent for business and investments.
Pell and Ben-Haim jointly founded several medical devices companies, which they sold for over $1 billion. The biggest success was Biosense Webster, in which Ben-Haim was also involved as an inventor, which was sold to Johnson & Johnson for $427 million in 1997. The company is still operating in Haifa, and market sources estimate its annual revenue at $500 million.
Other exits include Disc-O-Tech, which was acquired in 2006 for $220 million by Kyphon; Instent, acquired in 1996 for $200 million by Medtronic Inc. (NYSE: MDT); Impulse Dynamics, acquired in 2000 for $127 million by Guidant; X-Technologies, acquired in 2003 for $60 million by Guidant; and Odigo, acquired in 2002 by Comverse Technology Inc. (Nasdaq: CMVT) for $17 million.
The pace of exits has slowed in recent years, as the situation of medical devices companies has become more complicated, although deals are still made. In 2011, Radiancy, in which Ben-Haim was a shareholder, merged with PhotoMedex Inc. (Nasdaq: PHMD; TASE: PHMD) in a $174 million deal that gave Radiancy shareholders 75% of the merged company, which has a market cap of $300 million.
Ben-Haim has also become the focus of lawsuits. The first lawsuit was filed by Radiancy's founders in 2004. They alleged that he and Pell tried to dispossess them of their share of the company, using thuggish methods that included false accusations of sexual harassment. The lawsuit was ultimately settled.
A similar lawsuit was filed by the founders of RF Dynamics, who also accused Ben-Haim of acting like a gangster in his work relations with them, including sending notices to employees which said that the petitioners were thieves, which was why they were removed from their posts. At the time, sources close to Ben-Haim and the company said that no such remarks were ever made, and that the company's founders did not invent its technology, but were merely employees.
In contrast, other entrepreneurs who have worked, and currently work, with Ben-Haim are happy with the collaboration and their financial rewards. "I knew a completely different person, smarter than all of us and very fair. When there were problems, he was always a gentleman," said one entrepreneur.
Shlomo is a man of black and white," said an entrepreneur who worked closely with Ben-Haim until a falling out. "So you're either with him, or not with him, in which case you're out."
Ben-Haim has founded many companies, and over time, found it harder to support them. In 2008, he turned to the US and Israeli capital markets for the first time, raising $124 million in bonds for Medinvest Group LLC, mostly from foreign investors, for nine companies which he had founded since 2000. He invested $40 million of his own money. The companies included Core Dynamics Ltd. (the subject of the current lawsuit), in which Medinvest invested $17.9 million in 2009.
Published by Globes [online], Israel business news - www.globes-online.com - on October 3, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012
You comment was recieved and soon will be published.
Load more comments
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.